by Emily Burke, PhD | Feb 7, 2019 | Groundbreaking New Therapies in Development
Decoding The Gut-Brain Axis Earlier this week, a newly published study made headlines for showing a direct link between the gut microbiome and depression. For the past several years, scientists have suspected a link between bugs in the gut and neurological health.... 
by Emily Burke, PhD | Dec 7, 2016 | Neuroscience
Microbiome & Disease The biotech world is abuzz with talk of the latest microbiome startup launch Axial Biotherapeutics (Boston, MA). What caught our eye here at the WEEKLY is the company’s focus on the gut microbiome — the entire collection of microbes living in... 
by Emily Burke, PhD | May 26, 2015 | Metabolic & Cardiovascular Disease
The Race Against Nash A silent epidemic creeping upon the Western world pushed the headline grabbing acquisition of a Phase 1 non-alcoholic steatohepatitis (NASH) drug last week. Boehringer Ingelheim (Ingelheim, Germany) acquired Pharmaxis (Sydney, Autralia) due to... 
by Emily Burke, PhD | Feb 26, 2015 | Uncategorized
It’s a great time to be in biotech—new therapeutics are breaking ground faster than we can say “monoclonal antibody” and the technologies behind them are heavy with promise and potential. Our mission is to keep your industry knowledge up to date and the WEEKLY is here... 
by Emily Burke, PhD | Nov 13, 2014 | Uncategorized
Biotechnology is enjoying another banner year on Wall Street. Currently, there are at least 39 companies queued for an IPO. This led us at the WEEKLY to wonder: what is the actual science behind each company’s promise that leads public markets to invest billions... 
